Innovation Funding in Australia: What It Is and How It Can Help You

A practical guide to grants, the R&D Tax Incentive and commercialisation support for Australian businesses building and scaling new technology. Innovation funding is any structured route that helps your business cover the cost and risk of developing and commercialising new products, processes or services.

In Australia, that support runs through three connected areas:

1. Competitive grants and innovation finance
2. The R&D Tax Incentive
3. Commercialisation pathways that help you turn protected technology into revenue, including investor incentives such as the Early Stage Innovation Company (ESIC) scheme.

Some of this support is project-based and competitive. Some arrives through the tax system after you have already spent the money. Some only becomes useful once your technology is generating sales or attracting investment. Used well, innovation funding extends the runway of your Australian business, helps you carry technical risk, speeds up delivery and strengthens investor confidence. It also gives you a clearer story about what you are building, why it matters, and how the work will reach the market.

None of it is automatic, though. The Australian Taxation Office, funders and AusIndustry, all expect credible evidence, clearly separated costs, and a project that actually meets the rules of the program you are applying to.

What We Mean by “Innovation Funding”

When we talk about innovation funding, we mean funding and tax incentives that support genuine R&D, product development, commercialisation and IP-led growth. That covers non-dilutive grants, matched-funding programs, the R&D Tax Incentive linked to qualifying expenditure, and investor incentives like ESIC that help you raise capital against your intellectual property.

For Australian businesses and research organisations, business.gov.au and GrantConnect are the main places to search for Commonwealth-backed opportunities. Depending on your sector and stage, that might mean the Business Research and Innovation Initiative (BRII), the Industry Growth Program (IGP), Cooperative Research Centres Projects (CRC-P) grants, CSIRO Kick-Start, or a state or territory program. Australian companies can also compete for funding to test ideas and collaborate with universities, CSIRO or other research organisations.

A strong application needs a clearly defined problem, a credible technical and commercial plan, the right team, realistic costs and a measurable route to impact. Assessors typically ask about your contribution to the Australian economy, such as jobs, turnover, R&D spend, new collaborations, sovereign capability, regional development, exports, and new or improved products, services or processes.

Where Each Funding Route Fits in Your Innovation Journey

The most useful funding strategy starts with where you actually are. A feasibility-stage project needs something completely different from a revenue-generating product entering a regulated market. The job is to match your stage, risk profile, cash position, ownership structure and IP strategy to the right combination of support, not to chase every program that looks vaguely relevant.

Early-Stage Exploration and Feasibility

At the start, you are usually trying to determine whether an idea is technically feasible and commercially viable to pursue. Typical routes at this stage include:

• CSIRO Kick-Start: Matched funding of $20,000 to $60,000 to work directly with CSIRO researchers
• The Business Research and Innovation Initiative (BRII): The Business Research and Innovation Initiative (BRII) operates as a two-stage competitive program addressing nominated government challenges. Stage 1 (Feasibility): Successful applicants receive grants of up to $100,000 to test the feasibility of their proposed solutions. Stage 2 (Proof of Concept): Only select participants who complete Stage 1 are invited to submit a competitive application for up to $1 million to develop a working proof of concept. BRII runs in challenge-based rounds rather than operating continuously, and there are currently no rounds open for application. Keep an eye on business.gov.au for future round announcements.
• Industry Growth Program early-stage commercialisation grants: $50,000 to $250,000, subject to the program’s current application status (see below)
• Cooperative Research Centres Projects (CRC-P): Matched funding of $100,000 to $3 million for short-term, industry-led collaborations of up to three years. Projects generally require an SME lead applicant, at least two Australian industry entities (including at least one SME) and at least one Australian research organisation.

• State and territory programs: Such as NSW MVP Ventures, Queensland’s Ignite Ideas, or LaunchVic in Victoria
• Early collaboration through universities or CSIRO

This stage rewards focus. You need to explain the problem, why it matters, what is genuinely uncertain, and how you will test it.

Funders do not expect a finished product but obviously expect a credible plan.

What good looks like here is a clear project scope, a capable team and measurable outcomes. If you are partnering with a university, CSIRO or another research organisation, the partnership structure and your own cash contribution need to be spelled out. Programs like CSIRO Kick-Start and CRC-P are explicit about the importance of accurate costings, matched contributions and complete submissions.

Build and Iterate: Turning Prototypes into a Product

Once the feasibility case is stronger, the job changes. You might be turning a prototype into a product, running a pilot, improving reliability, or proving a system holds up under real operating conditions.

The Industry Growth Program’s larger commercialisation and growth stream ($100,000 to $5 million), sector-specific programs, and investor-linked support tend to fit here. The IGP is built for innovative Australian SMEs and startups whose projects align with National Reconstruction Fund (NRF) priority areas: renewables and low-emissions technologies, medical science, defence capability, value-add in resources, value-add in agriculture, forestry and fisheries, transport, and enabling capabilities.

A note on timing: the Industry Growth Program has been paused to new applications. If you are building a funding timeline around it, check business.gov.au for its current status first.

At this stage, funders look closely at delivery. They want to see technical risk but not confusion. Your application should explain the work packages, test plans, milestones, budget assumptions, regulatory pathway and delivery capacity. The strongest applications are specific: what will be tested, what success looks like, and what decisions get made at each stage.

Scale-Up and Commercialisation

As you move towards market adoption, the case becomes more commercial. You may still be solving technical problems, but funders will expect real detail on customers, pricing, manufacturing, regulation, supply chains, governance, working capital and the team delivering all of it. Relevant routes can include:

• Larger Industry Growth Program grants (subject to the program’s current pause).
• National Reconstruction Fund (NRF) debt or equity finance in priority sectors.
• Export Market Development Grants (EMDG) for market entry.
• The Supply Chain Resilience Initiative: grants of $50,000 to $2 million, generally covering up to 50% of eligible project expenditure, for manufacturing and manufacturing-supply-chain projects addressing vulnerabilities affecting critical products or inputs. The current round is closed.
• Sector-specific programs such as the Defence Industry Development Grants Program and the Net Zero Manufacturing Initiative.
• State and territory growth programs and strategic investment vehicles.

This is where a joined-up approach earns its keep. A grant might fund a defined project, but it usually will not cover every cost in the business. NRF finance can help with late-stage capability building, but it still needs a credible commercial story behind it. The R&D Tax Incentive might support your qualifying R&D costs, but the claim has to meet AusIndustry’s and the ATO’s specific definitions of core and supporting activities and their registration and claim processes.

IP and Profitable Growth

Australia does not currently run a Patent Box regime; an earlier proposal covering medical and biotechnology patents was not progressed, and there is no broad equivalent to the UK’s Patent Box. A patent by itself does not automatically reduce the tax rate on the profits it generates.

That does not make IP strategy any less important. Clear ownership, development evidence and commercialisation planning still decide whether you can attract investment, license technology, or get full value from your patents and other IP.

One route worth understanding here is the Early Stage Innovation Company (ESIC) scheme. It is not direct funding but an investor tax incentive that makes your company more attractive to outside investors. Eligible investors who buy new shares in a qualifying ESIC can access a 20% non-refundable, carry-forward tax offset on their investment, subject to applicable caps and investor rules, along with modified CGT (Capital Gains Tax) treatment on qualifying shares held for at least 12 months and less than 10 years. To qualify, your company generally needs to pass an “early stage” test (based on incorporation date, expenses and assessable income) and an “innovation” test, met either through a principles-based self-assessment or a 100-point innovation test. Getting this structured correctly before a capital raise can materially change how attractive your business looks to angel investors and early-stage VCs.

What good looks like here is clear IP ownership or exclusive licensing rights, a sensible product and revenue map, and records connecting the protected technology to income, cost and the R&D that created it. IP Australia handles trade marks, patents, designs and plant breeder’s rights, but commercial ownership, licensing structure and tax treatment need a broader review with your accountant or adviser. Planning early makes later commercialisation, licensing or exit discussions far smoother, and it strengthens any future R&D Tax Incentive or grant reporting.

The Funding Pillars, Explained Simply

Grants

Grants are competitive awards for defined projects because they are non-equity funding. Businesses in Australia can use grants to fund research and commercialisation without giving up ownership. The money is tied to the project: its scope, its eligible costs, and the terms of that specific program.

Funders usually want to understand four things:

1. The innovation itself
2. Its impact
3. Your delivery plan
4. Value for money.

Cash flow is where most people get caught out! Many grants in Australia are paid in arrears or against milestones, after you have incurred and evidenced the eligible costs, not upfront. If the program requires matched funding or a partner organisation, that needs to be locked in before you apply, not scrambled together afterwards. A strong grant application is not just a persuasive story. It is also a workable delivery plan with the cash flow to back it.

The R&D Tax Incentive

The R&D Tax Incentive (RDTI) is Australia’s largest innovation support program. It is a tax offset tied to qualifying R&D expenditure, not a reward for anything that merely feels innovative.

For tax purposes, core R&D activities are experimental activities whose outcome cannot be known or determined in advance based on current knowledge, and that are carried out to generate new knowledge. Supporting activities have to be directly related to that core work.

Under the current rules:

• Companies with aggregated turnover under $20 million can access a refundable offset equal to the company tax rate plus an 18.5 percentage point premium. For an eligible base-rate entity, this is currently 43.5%.

• Companies with aggregated turnover of $20 million or more receive a non-refundable offset at the company tax rate plus an intensity-based premium: 8.5% for R&D expenditure up to 2% of total expenditure, or 16.5% above that — up to a $150 million expenditure cap, beyond which the premium no longer applies.

• There’s a $20,000 minimum expenditure threshold (with limited exceptions, such as using a registered tax agent) and a $150 million expenditure cap, beyond which the premium no longer applies.
• Activities need to be registered with AusIndustry within 10 months of the end of your income year — by 30 April for a standard 30 June year-end — before you claim the offset through your company tax return with the ATO.
• Most R&D has to be conducted in Australia. Overseas activity needs an advance overseas finding from the Department of Industry, Science and Resources before it can be included.

Significant reforms are coming, announced in the 2026–27 Federal Budget on 12 May 2026. They are not law yet, and they will not take effect until income years starting on or after 1 July 2028, but the direction is clear enough to plan around. The seven changes on the table:

• Removing “supporting” R&D activities from the offset altogether, replacing them with a higher offset rate on core activities
• Lifting the core offset rate by 4.5 percentage points
• Lowering the intensity premium threshold from 2% to 1.5% of expenditure
• Restricting the refundable offset to a company’s first 10 years of operation
• Raising the minimum expenditure threshold from $20,000 to $50,000
• Lifting the turnover threshold for the refundable offset from $20 million to $50 million
• Raising the maximum expenditure cap from $150 million to $200 million

In practice, this rewards mature, high-intensity R&D programs and tightens things at the smaller, earlier-stage end. Particularly through the removal of supporting-activity eligibility and the higher minimum spend. If your R&D program is still young, it is worth understanding how these changes might affect you well before 2028, not after.

Until then, the current rules apply, and compliance is where the risk sits. You need clear, contemporaneous evidence of the technical or scientific uncertainty, the experiments run, the results (including the failures), and the costs claimed. Easy-to-verify record-keeping protects the claim and shortens any later review.

IP, Commercialisation Support and ESIC

Without a Patent Box, Australian innovators lean on two things instead: targeted commercialisation grants (like the Industry Growth Program, when it’s open) and investor incentives like ESIC, to get commercial value out of their IP.

Both require groundwork most companies leave too late. Whether you can access either depends on your income position, your commercialisation readiness, and your ownership or licensing structure in plain terms, who owns the IP, which entity earns the revenue, and how commercial benefits flow through the group. Programs like the Industry Growth Program, CRC Projects, CSIRO collaborations and state commercialisation funds all look closely at your IP position when assessing an application.

If you wait until the product is generating revenue to start thinking about this, you are often reconstructing ownership, development and cost records under pressure. Building the evidence trail as you go is far less painful.

How to Combine Grants, the R&D Tax Incentive and Commercialisation Support Without Tripping Up

These three routes work well together, but they have to be mapped out deliberately. Combining support is not the same as claiming twice for the same cost, the RDTI’s grant/recoupment adjustment rules exist specifically to catch that.

A simple stacking example across two to three years

In year one, you might use CSIRO Kick-Start or a state feasibility grant to test whether your technology is viable. At the same time, you start recording the technical uncertainty, the options you considered, the tests you ran, and what failed and why. That record supports your grant reporting now and your R&D Tax Incentive claim later.

In year two, the project moves into development. You apply for a larger commercialisation grant, or continue a collaborative research project, while tracking qualifying R&D activity separately from grant-funded costs and non-qualifying commercial work. This is where a grant/recoupment adjustment under the RDTI becomes relevant whether an adjustment applies depends on the character of the payment, the terms of the grant, its timing and the expenditure you’ve claimed. Clean cost separation from the start avoids a nasty surprise later.

In year three, the technology is closer to market, or already generating revenue. You review IP ownership and protection, map your income streams back to the underlying technology, and check that your cost and development records support both any ongoing R&D claim and commercialisation discussions with investors or partners, including whether an ESIC structure makes sense for your next capital raise. EMDG may also become relevant if you are heading into export markets.

This is the joined-up approach that works: understand what you are actually building, choose the funding mix that fits your situation, and build the case properly from day one rather than bolting evidence together after the fact.

The Rules and Risks to Watch

The biggest risk is treating each funding route in isolation. A grant can reduce the expenditure eligible for the R&D Tax Incentive if it funds the same activities. The RDTI requires careful separation of core experimental work from routine development or commercial activity. IP ownership affects both grant eligibility and commercial value later; if the entity doing the R&D is not the entity that owns the resulting IP or earns the income, you can run into real problems.

Subsidy and recoupment wording matters more than most people expect. You need to know whether a grant counts as a government contribution that reduces your eligible R&D expenditure, and how that interacts with the relevant RDTI provisions. Small differences in a grant agreement’s wording can change the analysis entirely; this is genuinely an area where specialist input pays for itself.

Timing is the other practical trap. Grants are often paid against milestones or in arrears. The RDTI is claimed after your income year ends, once registration and your tax return are lodged, so that cash lands later still. Your funding plan should reflect when the money actually arrives, not the headline value of each program.

What to Put in Place Now to Make Funding Easier Later

Evidence that works for funders, AusIndustry and the ATO

Good evidence is far easier to build during the project than to reconstruct afterwards. Your records should explain what was uncertain, what your team tried, what worked, what failed, and what changed as a result.

For grants, the evidence needs to show progress against scope, milestones and the impact case you promised. For the RDTI, it needs to connect the technical uncertainty to the experimental work and the costs claimed. For commercialisation and IP discussions, it needs to connect the protected rights, the development history, income and cost.

The habits that help across all three are the same: keep short project summaries, record key technical decisions as you make them, retain test results and design iterations, map staff time and third-party costs to specific activities, and reconcile everything back to payroll, invoices and the ledger.

Internal roles and accountability

A strong funding process needs clear ownership. Your technical lead should own the project narrative; they understand the uncertainty, the decisions and the evidence. Your finance lead should own the numbers; they understand payroll, invoices, accounting periods and reconciliations. Both need to talk to each other throughout the year, not just at year-end.

The alternative is the familiar scramble: finance has the costs but not the R&D story, and the technical team remembers the work but not the evidence trail. A simple monthly rhythm to review active projects, confirm what’s changed, capture key evidence, and check that costs are coded usefully beats a big clean-up exercise every time.

How to Choose the Right Mix for Your Business

The right mix depends on your stage, risk profile, cash position, timeline, sector and IP strategy. Honestly, there is no single correct order to apply for things.

If you are still exploring the technical case, CSIRO Kick-Start, BRII, an early-stage program, or a collaborative research route like CRC-P is usually the right starting point. If you are closer to market and need patient capital or larger matched funding, the commercialisation and growth stream of the Industry Growth Program (when open) or NRF pathways in priority sectors are worth reviewing. If you are already spending on qualifying R&D, the RDTI should be considered alongside your grant strategy, not as an afterthought once the grant process is done.

IP and commercialisation planning matters more as patents, protection or revenue come into view, but the groundwork should start earlier than that. Ownership, licensing, product mapping and cost tracking all affect whether later commercialisation or an ESIC-backed capital raise is actually practical.

Specialist input earns its keep where the facts get complicated: grant-funded R&D and recoupment adjustments, group structures, overseas R&D activity, contracted or outsourced R&D, investor-linked funding, university and CRC collaborations, and cases where IP sits in a different entity from the trading business. In these situations, the value is not just finding funding but building a compliant, well-documented position from the start.

Common Myths That Hold Teams Back

“We’re too small.” Size doesn’t decide everything. Many programs are built specifically for SMEs and startups, and RDTI eligibility depends on whether your company, activities and costs meet the criteria, not on how many people you employ.

“It’s just normal product development.” Some product development is routine. Some involves genuine scientific or technological uncertainty. The real question isn’t whether you were building a product; it is whether the project sought an advance through experimental activities whose outcome a competent professional couldn’t have known in advance.

“We already got a grant, so the R&D Tax Incentive doesn’t apply.” Too simple. A grant can affect your eligible expenditure through the grant/recoupment adjustments rules, but it does not automatically wipe out your RDTI position. The answer depends on the grant’s terms, the activities it funded, your accounting period and the scheme rules.

“A patent automatically creates a tax benefit and IP support is only for big companies or pharma.” Also wrong. A patent may strengthen your commercialisation and investment case, but it does not create an automatic reduced tax rate in Australia. And clear IP ownership and commercialisation planning matter for any innovative business chasing investment or protecting a competitive edge not just large companies in life sciences.

“Government funding is only for universities.” Startups and SMEs can access BRII, CRC-P, the Industry Growth Program and state or territory programs directly, provided their project meets the relevant eligibility and merit criteria and the relevant rounds are open.

“Scale-up funding is only for massive companies.” Programs exist right across the spectrum from early-stage MVP grants through to substantial support for advanced manufacturing. What decides access is your IP, ownership, development records and data position, not your headcount.

How can Pattens Group help?

We help Australian businesses, startups and research organisations choose the right innovation funding route, then build the case properly. Our team brings together STEM, sector and tax expertise across high-impact areas like AI, automation, clean energy, hydrogen, life sciences, software, advanced manufacturing, food and fibre, resources, space, and defence-related technologies. To date, we have helped Australian businesses secure more than $300 million in funding and delivered over 2,000 claims across a wide range of sectors.

We connect grants, the R&D Tax Incentive and commercialisation pathways, including ESIC, into a single funding strategy, with well-documented evidence behind every submission. The goal is not to chase every program that exists. It is to identify the support that actually fits your project, your cash position, your ownership structure and your commercial pathway.

If you are planning a grant application, investing in R&D, developing a new manufacturing capability, or preparing to commercialise protected technology, book a free assessment with our funding advisers. We will help you understand what support may realistically be available and what to do next. You can also check your eligibility online to get a first read on whether your business could access grants, the R&D Tax Incentive, or other innovation support.

Funding programs, eligibility rules, rates and program status change regularly — the Industry Growth Program’s pause to new applications is one recent example. Confirm current program guidance and get tailored tax advice before relying on any funding or R&D claim.

Accurate as at 14 September 2026.